The Avicenna Alliance provided feedback on the Pharmaceutical Strategy for Europe
We are proud to announce that the Avicenna Alliance has submitted Members’ feedback to the European Commission’s Roadmap on the Pharmaceutical Strategy for Europe! This document has been developed by members of the Avicenna Alliance from medtech, pharmaceutical, software and life science industries and scientific community from academia.
This feedback period was highly important for the Avicenna Alliance as the overall goal of the pharmaceutical strategy initiative is to help ensure EU’s supply of safe and affordable medicines to meet patients’ needs and support the European pharmaceutical industry to remain an innovator and world leader.
The Avicenna Alliance underlines the need to better harness technological and scientific developments such as medical technologies, including artificial intelligence (AI). In particular, our contribution aims to enhance the role of computer modelling and simulation (CM&S) in four main areas:
- A greater access and availability of pharmaceuticals to patients;
- The affordability of medicines for patients and health systems financial and fiscal sustainability;
- Innovation including for unmet medical needs in harnessing the benefits of digital and emerging science and technology while reducing the environmental footprint;
- To support EU influence and competitiveness on the global level, reduce direct dependence on manufacturing from non-EU countries seek a level playing field for EU operators.
The Avicenna Alliance is therefore proud to share with you the common feedback provided to the European Commission’s Roadmap on the Pharmaceutical Strategy for Europe!
We would like to thank Avicenna Members for their contributions, and more particularly, Voisin Life Sciences Consulting, Servier, the VPH Institute, QUIBIM, Mediolanum Cardio Research, Ansys, inSilicoTrials Technologies and Dassault Systèmes!